Novartis Ag (NVS) EBT Margin (2009 - 2026)

Novartis Ag (NVS) posted EBT Margin of 29.63% for Q2 2026, down 8.1% sequentially from 32.24% in Q2 2025, and down 261.0% YoY from 18.4% in Q2 2025.

Novartis Ag (NVS) EBT Margin (2009 - 2026) Analysis & Trends

Novartis Ag has reported EBT Margin for 18 years, with the latest figure at 29.63% in Q2 2026.

Quarterly EBT Margin fell 261.0% year-over-year to 29.63% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 126.37% (up 8613.0% YoY) and the FY2025 annual result came in at 29.99%, up 288.0% from the prior year.
EBT Margin retreated to 29.63% in Q2 2026 per NVS's latest filing, from 32.24% in the prior quarter.
Over five years, EBT Margin peaked at 13229930.74% in Q1 2022 and troughed at 15.98% in Q2 2022.
A 5-year average of 1343092.02% and a median of 29.63% in 2026 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2023: EBT Margin soared 824739764 bps in 2022, then tumbled 1168642426 bps in 2023.
Over 5 years, EBT Margin stood at 18.61% in 2022, then climbed by 26 bps to 23.36% in 2023, then increased by 23 bps to 28.63% in 2024, then grew by 13 bps to 32.24% in 2025, then slipped by 8 bps to 29.63% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 29.63%, 32.24%, and 28.63% for Q2 2026, Q2 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	26.66%
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	25.18%
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-4.11%
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	29.63%
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	18.19%
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	27.53%
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	-131.41%
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	-4.34%
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	4.21%
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	127.52%

Download Data